- You can view the full Valeant Pharmaceuticals International Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
JPMorgan expects Valeant (VRX) to cut its 2016 full-year earnings guidance and said it is 'cautious' on the stock.
Legendary value investor Bill Miller called Valeant Pharmaceuticals (VRX) the 'most toxic' stock in the market, but explained why he just bought more.